Results from the CHOICE study suggest that both a 150 mg and 300 mg dose of secukinumab improved symptoms of psoriatic arthritis (PsA) in biologic-naïve patients, with higher response rates for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results